About: How we treat patients with brain tumour during the COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: How we treat patients with brain tumour during the COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	How we treat patients with brain tumour during the COVID-19 pandemic
Creator	Weller, M Esmo Open, Preusser, M
Source	Medline; PMC
abstract	The COVID-19 pandemic has created major insecurities regarding whether we can and should maintain the current standards of diagnosis and treatment and access to care for patients with cancer. This is particularly true in the field of neuro-oncology, where the perceived benefit of therapeutic interventions is often low, although this notion is partially incorrect. We acknowledge that the recommendations for care of patients with cancer have become a moving target and that all recommendations are subject to modification based on national and institutional regulations. Still, some important considerations and proposals may apply broadly. First, it is important to note that old age and cardiovascular and pulmonary co-morbidities are the major risk factors for experiencing a severe course of and for dying of COVID-19, not chronic immunosuppression and cancer. Second, many of the considerations on how we should adapt clinical practice in neuro-oncology in view of COVID-19 that are now dominating discussions at local tumour boards, as well as on the institutional level and within societies of neuro-oncology, are not novel but have been valid before and only now have become a priority. More than ever, it seems to be mandatory to adhere to evidence-based medicine and not to prescribe potentially toxic, notably immunsuppresssive systemic therapy where evidence for efficacy is low. Furthermore, it is more obvious now that oncologists must not miss the right time for advance care planning, that is, supporting patients in understanding and sharing their personal values, life goals and preferences regarding future medical care. The major psychological impact of transforming oncology care to teleconferences and videoconferences and of the important strict recommendation of social distancing must not be overlooked in a patient population that is characterised by significant prevalence of cognitive decline and by the general perception that their life span may not exceed the life span of the COVID-19 pandemic
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1136/esmoopen-2020-000789
bibo:pmid	32409298
has license	cc-by-nc
sha1sum (hex)	2e3b9a7cd590e2d0e26811f63c9c2ec61ff06922
schema:url	https://doi.org/10.1136/esmoopen-2020-000789
resource representing a document's title	How we treat patients with brain tumour during the COVID-19 pandemic
has PubMed Central identifier	PMC7234866
has PubMed identifier	32409298
schema:publication	ESMO Open
resource representing a document's body	covid:2e3b9a7cd590e2d0e26811f63c9c2ec61ff06922#body_text
is schema:about of	named entity 'HOW' named entity 'COVID-19 PANDEMIC' named entity 'BRAIN TUMOUR' named entity 'patients' named entity 'treat patients' named entity 'schwannomas' named entity 'scientifically false' named entity 'risk factor' named entity 'COVID-19' named entity 'irradiation' named entity 'promoter methylation' named entity 'brain tumour' named entity 'life span' named entity 'radiochemotherapy' named entity 'elderly patients' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'chemotherapy' named entity 'MGMT' named entity 'steroids' named entity 'risk factors' named entity 'COVID-19' named entity 'meningioma' named entity 'steroid' named entity 'oncologists' named entity 'neuro-oncology' named entity 'MGMT' named entity 'glioblastoma' named entity 'radiotherapy' named entity 'brain metastases' named entity 'pharmacotherapy' named entity 'prognosis' named entity 'performance status' named entity 'COVID-19 pandemic' named entity 'astrocytoma' named entity 'MGMT' named entity 'asymptomatic' named entity 'Clinical trials' named entity 'glioblastoma' named entity 'standard of care' named entity 'platinum-based' named entity 'chemotherapy' named entity 'nitrosoureas' named entity 'glioblastoma' named entity 'Wuhan' named entity 'COVID-19' named entity 'social distancing' named entity 'promoter methylation' named entity 'COVID-19 pandemic' named entity 'clinical trials' named entity 'relative risks' named entity 'COVID-19' named entity 'pulmonary toxicity' named entity 'placebo-controlled trials' named entity 'comorbidity' named entity 'COVID-19' named entity 'neurooncology' named entity 'clinical research' named entity 'advance care planning' named entity 'temozolomide' named entity 'Creative Commons' named entity 'advance care planning' named entity 'healthcare providers' named entity 'alkylating agent' named entity 'asymptomatic' named entity 'COVID-19' named entity 'systemic therapy' named entity 'CoVid-19' named entity 'clinical trials' named entity 'Radiotherapy' named entity 'steroids' named entity 'Brain tumour' named entity 'MGMT' named entity 'open access' named entity 'chemotherapy' named entity 'chemotherapies' named entity 'comorbidity' named entity 'glioblastoma' named entity 'risk factors' named entity 'temozolomide'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software